|
1
|
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
|
Lancet
|
2002
|
16.56
|
|
2
|
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
|
Lancet
|
2009
|
14.01
|
|
3
|
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
|
JAMA
|
2004
|
10.40
|
|
4
|
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America.
|
Clin Infect Dis
|
2005
|
5.20
|
|
5
|
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.
|
Lancet
|
2006
|
5.00
|
|
6
|
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
|
Nat Med
|
2005
|
4.83
|
|
7
|
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.
|
Lancet
|
2004
|
3.59
|
|
8
|
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
|
Lancet
|
2006
|
2.85
|
|
9
|
Chronic renal failure among HIV-1-infected patients.
|
AIDS
|
2007
|
2.07
|
|
10
|
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.
|
Clin Infect Dis
|
2009
|
1.86
|
|
11
|
Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
|
Arch Intern Med
|
2006
|
1.69
|
|
12
|
Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.
|
AIDS
|
2002
|
1.63
|
|
13
|
Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease.
|
J Virol
|
2010
|
1.61
|
|
14
|
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
|
Nephrol Dial Transplant
|
2005
|
1.49
|
|
15
|
Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART.
|
AIDS Read
|
2005
|
1.40
|
|
16
|
Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients.
|
J Acquir Immune Defic Syndr
|
2002
|
1.37
|
|
17
|
Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country.
|
AIDS
|
2008
|
1.36
|
|
18
|
Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients.
|
AIDS
|
2009
|
1.34
|
|
19
|
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
|
AIDS
|
2008
|
1.23
|
|
20
|
Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
|
Antivir Ther
|
2008
|
1.21
|
|
21
|
The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study.
|
AIDS
|
2008
|
1.18
|
|
22
|
Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
|
AIDS
|
2005
|
1.16
|
|
23
|
Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214.
|
Antimicrob Agents Chemother
|
2003
|
1.14
|
|
24
|
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.
|
Arch Intern Med
|
2010
|
1.12
|
|
25
|
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
|
AIDS
|
2008
|
1.11
|
|
26
|
Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity.
|
Nephrol Dial Transplant
|
2004
|
1.10
|
|
27
|
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
|
Eur J Clin Pharmacol
|
2007
|
1.09
|
|
28
|
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
|
AIDS
|
2007
|
1.07
|
|
29
|
Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
|
J Antimicrob Chemother
|
2005
|
1.06
|
|
30
|
An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.
|
AIDS
|
2003
|
1.05
|
|
31
|
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.
|
AIDS
|
2002
|
1.05
|
|
32
|
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
|
J Infect Dis
|
2002
|
1.05
|
|
33
|
Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.
|
J Acquir Immune Defic Syndr
|
2009
|
1.04
|
|
34
|
Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.
|
Antivir Ther
|
2005
|
1.03
|
|
35
|
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.
|
AIDS
|
2004
|
1.00
|
|
36
|
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.
|
Br J Clin Pharmacol
|
2006
|
0.99
|
|
37
|
Comparison of nine resistance interpretation systems for HIV-1 genotyping.
|
Antivir Ther
|
2003
|
0.96
|
|
38
|
The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
|
J Antimicrob Chemother
|
2008
|
0.95
|
|
39
|
Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
|
Antivir Ther
|
2007
|
0.95
|
|
40
|
New drugs for HIV therapy.
|
AIDS
|
2002
|
0.92
|
|
41
|
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
|
AIDS
|
2008
|
0.91
|
|
42
|
Evaluation of the LiPA HIV-1 RT assay version 1: comparison of sequence and hybridization based genotyping systems.
|
J Clin Virol
|
2002
|
0.91
|
|
43
|
Prevalence- and gender-specific immune response to opportunistic infections in HIV-infected patients in Lesotho.
|
Sex Transm Dis
|
2010
|
0.89
|
|
44
|
Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
|
Antimicrob Agents Chemother
|
2007
|
0.88
|
|
45
|
Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals.
|
J Acquir Immune Defic Syndr
|
2004
|
0.88
|
|
46
|
Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma.
|
Eur J Immunol
|
2007
|
0.88
|
|
47
|
Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1.
|
Antimicrob Agents Chemother
|
2007
|
0.87
|
|
48
|
Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.
|
Antivir Ther
|
2008
|
0.85
|
|
49
|
Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.
|
Antimicrob Agents Chemother
|
2006
|
0.85
|
|
50
|
Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
|
Antivir Ther
|
2007
|
0.83
|
|
51
|
Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2.
|
HIV Med
|
2007
|
0.81
|
|
52
|
Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
|
Antivir Ther
|
2007
|
0.81
|
|
53
|
Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks.
|
HIV Clin Trials
|
2003
|
0.80
|
|
54
|
Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
|
Antivir Ther
|
2007
|
0.80
|
|
55
|
Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
|
Curr HIV Res
|
2009
|
0.79
|
|
56
|
Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis.
|
Scand J Infect Dis
|
2005
|
0.78
|
|
57
|
Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
|
HIV Clin Trials
|
2009
|
0.78
|
|
58
|
A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure.
|
AIDS Res Hum Retroviruses
|
2003
|
0.78
|
|
59
|
Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection.
|
AIDS
|
2008
|
0.78
|
|
60
|
[No obvious difference in Streptococcus pneumoniae antibiotic resistance profiles--isolates from HIV-positive and HIV-negative patients].
|
Med Klin (Munich)
|
2008
|
0.77
|
|
61
|
Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen.
|
Antimicrob Agents Chemother
|
2008
|
0.76
|
|
62
|
Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors.
|
J Antimicrob Chemother
|
2008
|
0.76
|
|
63
|
Use of bioelectrical impedance analysis to determine body composition changes in HIV-associated wasting.
|
Int J STD AIDS
|
2005
|
0.75
|
|
64
|
Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient.
|
AIDS
|
2004
|
0.75
|
|
65
|
Short communication: Different mutation patterns in subtype CRF06_cpx after mother-to-child transmission.
|
AIDS Res Hum Retroviruses
|
2008
|
0.75
|
|
66
|
Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial.
|
J Acquir Immune Defic Syndr
|
2005
|
0.75
|
|
67
|
Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy.
|
Scand J Infect Dis
|
2007
|
0.75
|